Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia-Reference-Cited by-同舟云学术

Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

Published:2016-11-28 Issue:7 Volume:58 Page:1764-1766
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Orlandi Ester Maria¹^ORCID,Elena Chiara¹²,Bono Elisa³

Affiliation:

1. Department of Oncology-Hematology, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;

2. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

3. Department of Oncology-Hematology, School of Hematology, University of Pavia, Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1260127

Reference15 articles.

1. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013

2. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study Epilymph

3. Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy

4. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis;Liver International;2024-08-29

2. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments;World Journal of Gastroenterology;2024-07-07

3. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors;World Journal of Gastroenterology;2024-06-28

4. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer;Cancers;2023-03-14

5. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion;Journal of Hepatology;2022-12